Targeting DNA Repair in Breast Cancer: PARP Inhibitors and B
Thousands of breast cancer researchers and physicians from around the world are gathered this week at the San Antonio Breast Cancer Symposium (SABCS). One topic that is sure to garner a lot of attention is DNA repair. The two most famous genes associated with breast cancer — BRCA1 and BRCA2 — are involved in the DNA repair pathway, and drugs targeting this pathway are now a promising avenue of treatment.

The first drugs of this type to become available were PARP inhibitors. The FDA approved the PARP inhibitor olaparib (Lynparza™) in 2014 for the treatment of advanced ovarian cancer in women with inherited BRCA mutations. Clinical trials of PARP inhibitors in women with breast cancer are ongoing.

To find out more about the current status of treatments that target DNA repair pathways, we spoke with Simon Powell, Chair of Radiation Oncology at Memorial Sloan Kettering. Dr. Powell is an expert in the molecular biology of DNA repair and is speaking on the topic today at SABCS. We interviewed Dr. Powell in advance of his talk....

https://www.mskcc.org/blog/targeting-dna-repair-breast-cancer-parp-inhibitors-and-beyond?
Like
Comment
Share